252 related articles for article (PubMed ID: 38266151)
1. Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.
Rutherford SC; Yin J; Pederson LD; Blum KA; Martin P; Jung SH; Grant B; Rosenbaum C; Cheson BD; Bartlett NL; Mandrekar SJ; Leonard JP
Blood Adv; 2024 Mar; 8(6):1464-1468. PubMed ID: 38266151
[No Abstract] [Full Text] [Related]
2. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Persky DO; Dornan D; Goldman BH; Braziel RM; Fisher RI; Leblanc M; Maloney DG; Press OW; Miller TP; Rimsza LM
Haematologica; 2012 Jun; 97(6):937-42. PubMed ID: 22271896
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and treatment of follicular lymphoma.
Hitz F; Ketterer N; Lohri A; Mey U; Pederiva S; Renner C; Taverna C; Hartmann A; Yeow K; Bodis S; Zucca E
Swiss Med Wkly; 2011; 141():w13247. PubMed ID: 21815111
[TBL] [Abstract][Full Text] [Related]
4. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
[TBL] [Abstract][Full Text] [Related]
5. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.
Sarkozy C; Seymour JF; Ferme C; Caballero D; Ghesquieres H; Leppa S; Delarue R; Pedersen LM; Mounier C; Gomes Da Silva M; Chassagne-Clement C; Maerevoet M; Salles G
Blood; 2014 Apr; 123(17):2740-2. PubMed ID: 24764560
[No Abstract] [Full Text] [Related]
6. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
7. Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?
Pettengell R
Drugs; 2009; 69(13):1727-37. PubMed ID: 19719330
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.
Kahl B
Semin Hematol; 2008 Apr; 45(2):90-4. PubMed ID: 18381103
[TBL] [Abstract][Full Text] [Related]
9. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
Le Gouill S; De Guibert S; Planche L; Brice P; Dupuis J; Cartron G; Van Hoof A; Casasnovas O; Gyan E; Tilly H; Fruchart C; Deconinck E; Fitoussi O; Gastaud L; Delwail V; Gabarre J; Gressin R; Blanc M; Foussard C; Salles G;
Haematologica; 2011 Aug; 96(8):1128-35. PubMed ID: 21486862
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
11. Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma.
Cohen JB; Kahl BS
Hematol Oncol Clin North Am; 2020 Aug; 34(4):663-672. PubMed ID: 32586572
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
Grant BW; Jung SH; Johnson JL; Kostakoglu L; Hsi E; Byrd JC; Jones J; Leonard JP; Martin SE; Cheson BD
Cancer; 2013 Nov; 119(21):3797-804. PubMed ID: 23922187
[TBL] [Abstract][Full Text] [Related]
13. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
14. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study.
Nabhan C; Byrtek M; Taylor MD; Friedberg JW; Cerhan JR; Hainsworth JD; Miller TP; Hirata J; Link BK; Flowers CR
Cancer; 2012 Oct; 118(19):4842-50. PubMed ID: 22434428
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Leahy MF; Turner JH
Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
[TBL] [Abstract][Full Text] [Related]
16. Treatment of follicular lymphoma--a review.
Van Hende V; Offner F
Acta Clin Belg; 2007; 62(6):408-18. PubMed ID: 18351185
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in lymphoma: the first decade.
Link BK; Friedberg JW
Semin Hematol; 2008 Apr; 45(2):71-4. PubMed ID: 18381100
[TBL] [Abstract][Full Text] [Related]
18. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
Roy R; Gordon LI
J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
[TBL] [Abstract][Full Text] [Related]
19. The cytokines and the B-cell malignancies: a new spin on maximizing therapeutic outcomes.
Snively AH
ONS News; 2006; 21(8 Suppl):13-4. PubMed ID: 16925132
[No Abstract] [Full Text] [Related]
20. Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma.
Younes A; Hariharan K; Allen RS; Leigh BR
Clin Lymphoma; 2003 Mar; 3(4):257-9. PubMed ID: 12672278
[No Abstract] [Full Text] [Related]
[Next] [New Search]
